The ACE inhibitor/ARB with eplerenone group reported 1% change in peak strain which was found to be clinically significant; however, this effect might be short-lived as disease pathology eventually negates the positive cardiac remodeling caused by these drugs. A study by Wang et al. [66] and Packer [67] have reported similar findings where they found the effect of ACE inhibitors/ARBs to be transient in a DMD cohort and an adult heart pathology population. This evidence concerns the gene ACE and Duchenne muscular dystrophy.